Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine

Cancer Research

Volumn 64, Issue 11, 2004, Pages 4001-4009

  De Giovanni, Carla ^a,g   Nicoletti, Giordano ^b   Landuzzi, Lorena ^b   Astolfi, Annalisa ^a   Croci, Stefania ^a   Comes, Alberto ^c   Ferrini, Silvano ^c   Meazza, Raffaella ^d   Iezzi, Manuela ^e   Di Carlo, Emma ^e   Musiani, Piero ^e   Cavallo, Federica ^f   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g Cancer Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION PROFILING; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPROPHYLAXIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; CANCER VACCINES; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; INTERLEUKIN-12; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTOR, ERBB-2; TRANSFECTION; VACCINATION;

EID: 2542609804     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2984     Document Type: Article

References (52)

1. Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res 2000;60:2571-5.
2. Finn OJ, Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 2002;14:172-7.
3. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002;51:409-16.
4. Lollini PL, Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003;24:62-6.
5. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
6. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
7. Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene 2000;19:6130-7.
8. Dranoff G. Coordinated tumor immunity. J Clin Invest 2003;111:1116-8.
9. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
10. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003;100:9464-9.
11. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998;47:183-90.
12. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001;167:3367-74.
13. Pupa SM, Invemizzi AM, Forti S, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001;8:75-9.
14. Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999;47:337-42.
15. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000;60:3782-9.
16. Dela Cruz JS, Lau SY, Ramirez EM, et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 2003;21:1317-26.
17. Cefai D, Morrison BW, Sckell A, et al. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 1999;83:393-400.
18. Reilly RT, Gottlieb MB, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
19. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-205.
20. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995;1:644-8.
21. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
22. Reilly RT, Machiels JP, Emens LA, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880-3.
23. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
24. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111:1161-70.
25. Renard V, Sonderbye L, Ebbehoj K, et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 2003;171:1588-95.
26. Wolpoe ME, Lutz ER, Ercolini AM, et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161-9.
27. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003;170:1980-6.
28. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
29. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
30. Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 2003;52:133-44.
31. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
32. Thomson, A. The Cytokine Handbook, Ed. 3. San Diego, CA: Academic Press, 1998.
33. Dols A, Smith JW, Meijer SL, et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003;14:1117-23.
34. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
35. Nanni P, Pupa SM, Nicoletti G, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94.
36. Lollini PL, Bosco MC, Cavallo F, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer 1993;55:320-9.
37. Lollini PL, De Giovanni C, Landuzzi L, et al. Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth. Hum Gene Ther 1995;6:743-52.
38. Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med 1989;169:13-25.
39. Di Carlo E, Comes A, Basso S, et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000;165:3111-8.
40. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
41. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/ Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
42. Di Carlo E, Diodoro MG, Boggio K, et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999;79:1261-9.
43. Ferrini S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985;36:337-43.
44. De Giovanni C, Landuzzi L, Nicoletti G, et al. Apc 10.1: An ApcMin/+ intestinal cell line with retention of heterozygosity. Int J Cancer 2004;109:200-6.
45. Meazza R, Lollini PL, Nanni P, et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000;87:574-81.
46. Gaggero A, Azzarone B, Andrei C, et al. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur J Immunol 1999;29:1265-74.
47. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49.
48. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997;89:1049-58.
49. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996;93:11798-801.
50. Blankenstein T, Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 2003;15:148-54.
51. Lenzi R, Rosenblum M, Verschraegen C, et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002;8:3686-95.
52. Cifaldi L, Quaglino E, Di Carlo E, et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 2001;61:2809-12.